XML 45 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 35 Months Ended 45 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Feb. 28, 2009
Feb. 28, 2009
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Total revenue     $ 24,364 $ 42,888 $ 62,793 $ 67,288      
Deferred Revenue     25,234   25,234       $ 6,547
Drug Product Revenue [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Total revenue     (8,648) $ 8,238 (168) $ 8,238      
Deferred Revenue     11,200   $ 11,200        
Astellas Agreement [Member] | Japan [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront, non-contingent and time-based payments received               $ 40,100  
Potential milestone payments   $ 132,500              
Commercial sales milestone   15,000              
Additional consideration based on net sales description         the low 20% range of the list price        
Aggregate consideration received excluding drug product revenue     105,100   $ 105,100        
Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential milestone payments   22,500              
Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential milestone payments   $ 95,000              
Astellas Agreement [Member] | Japan [Member] | Drug Product Revenue [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Total revenue     (2,000)   $ 2,100        
Astellas Agreement [Member] | Europe [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront, non-contingent and time-based payments received             $ 320,000    
Additional consideration based on net sales description         low 20% range        
Aggregate consideration received excluding drug product revenue     540,000   $ 540,000        
Development and regulatory approval milestones $ 425,000                
Percentage of joint development costs committed to fund 50.00%                
Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential milestone payments $ 90,000                
Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential milestone payments $ 335,000                
Astellas Agreement [Member] | Europe [Member] | Drug Product Revenue [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Deferred Revenue     $ 11,800   $ 11,800